Your browser is no longer supported. Please, upgrade your browser.
SHPG Shire plc daily Stock Chart
Shire plc
Index- P/E64.75 EPS (ttm)2.79 Insider Own0.10% Shs Outstand296.43M Perf Week5.92%
Market Cap53.55B Forward P/E10.36 EPS next Y17.43 Insider Trans0.00% Shs Float181.63M Perf Month11.71%
Income603.50M PEG5.04 EPS next Q3.40 Inst Own22.70% Short Float0.52% Perf Quarter0.23%
Sales11.40B P/S4.70 EPS this Y-65.50% Inst Trans-1.98% Short Ratio0.89 Perf Half Y-9.53%
Book/sh96.20 P/B1.88 EPS next Y15.15% ROA0.60% Target Price240.85 Perf Year10.76%
Cash/sh1.78 P/C101.27 EPS next 5Y12.85% ROE1.30% 52W Range149.95 - 209.22 Perf YTD6.03%
Dividend0.80 P/FCF- EPS past 5Y-12.80% ROI2.10% 52W High-13.66% Beta1.54
Dividend %0.44% Quick Ratio0.50 Sales past 5Y22.30% Gross Margin66.50% 52W Low20.47% ATR3.44
Employees5548 Current Ratio1.00 Sales Q/Q121.80% Oper. Margin8.40% RSI (14)69.13 Volatility2.15% 1.66%
OptionableYes Debt/Eq0.79 EPS Q/Q9.30% Profit Margin2.90% Rel Volume0.97 Prev Close181.08
ShortableYes LT Debt/Eq0.69 EarningsFeb 16 BMO Payout40.20% Avg Volume1.06M Price180.65
Recom1.70 SMA206.56% SMA506.44% SMA200-0.92% Volume1,035,151 Change-0.24%
Dec-02-16Initiated Societe Generale Buy
Sep-26-16Downgrade HSBC Securities Buy → Hold
Jun-03-16Reiterated Jefferies Buy $223 → $262
May-26-16Initiated Stifel Buy $230
May-06-16Initiated Liberum Buy
Feb-26-16Initiated Cantor Fitzgerald Buy
Feb-10-16Upgrade RBC Capital Mkts Sector Perform → Outperform $240 → $240
Feb-10-16Initiated Guggenheim Neutral
Jan-15-16Upgrade BofA/Merrill Neutral → Buy
Jan-12-16Upgrade Credit Suisse Neutral → Outperform
Jan-12-16Reiterated RBC Capital Mkts Sector Perform $248 → $240
Nov-17-15Upgrade Leerink Partners Mkt Perform → Outperform $239
Nov-03-15Upgrade HSBC Securities Hold → Buy
Oct-26-15Reiterated RBC Capital Mkts Sector Perform $263 → $248
Oct-14-15Initiated Northland Capital Outperform $288
Sep-30-15Upgrade HSBC Securities Reduce → Hold
Aug-06-15Downgrade Exane BNP Paribas Outperform → Neutral
Jul-16-15Resumed Berenberg Buy
Apr-29-15Initiated Exane BNP Paribas Outperform
Jan-26-15Reiterated RBC Capital Mkts Sector Perform $238 → $248
Feb-21-17 02:01PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
09:27AM  Shire Plc :SHPG-US: Earnings Analysis: Q4, 2016 By the Numbers : February 21, 2017
Feb-20-17 09:57AM  3 Stocks to Invest in Big Pharma at Motley Fool
Feb-17-17 02:04PM  Shire (SHPG) Beats on Q4 Earnings, Sales; Gives Upbeat View
01:50PM  Shire PLC 4Q Earnings, Revenue Beat Street at Investopedia
01:08PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
Feb-16-17 04:28PM  Drugmaker Shire Tops Q4 Views; Stock Pops To Six-Week High
08:14AM  Shire beats Street 4Q forecasts
07:52AM  Shire Reports Full Year 2016 Results With Record Revenue; Positioned for Continued Strong Growth Driven by Best-in-class Rare Disease Pipeline PR Newswire
07:25AM  Shire Beats Full-Year Earnings Estimates, Sees Robust 2017 Growth
Feb-15-17 04:24PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
12:49PM  Amicus Therapeutics Updates Migalastat Drug at Investopedia
Feb-14-17 07:30AM  Shire to Highlight Advancements in Rare Genetic Diseases PR Newswire
Feb-08-17 10:04AM  Shire ViroPharma Sued By FTC Over Sham FDA Filings at Investopedia
Feb-07-17 04:05PM  FTC says Shire unit used illegal tactics to block generic competition at
03:42PM  Shire Responds to U.S. Federal Trade Commission Civil Action PR Newswire
10:45AM  Hemophilia Drug Market Competitive Ramps Up at Investopedia
Feb-02-17 10:40AM  5 Drugmakers Battle Over the $10 Billion Hemophilia Market at Motley Fool
Feb-01-17 03:49PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
01:39PM  New Data From Shire Aim to Help Close the Diagnosis and Treatment Gap for People With Hemophilia PR Newswire
Jan-27-17 12:20PM  Keeley All Cap Value Fund Comments on Shire
Jan-26-17 08:25AM  Drug Giants May Benefit From China Drug Inclusion at Investopedia
Jan-25-17 01:10PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
Jan-23-17 11:27AM  5 Stupendously Expensive Cancer Drugs at Motley Fool
Jan-20-17 05:50PM  Shire's (SHPG) ADHD Candidate's NDA Accepted by FDA
Jan-19-17 10:00AM  Is Shire plc a Great Stock for Value Investors?
07:00AM  U.S. FDA Acknowledges Receipt of Shire's New Drug Application for SHP465 for ADHD PR Newswire
Jan-18-17 12:37PM  Alcobra Stock Down on Poor Late-Stage Data on ADHD Drug
Jan-17-17 12:24PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
Jan-13-17 11:56AM  FTSE 100 continues record run, rising for 14th day in a row at MarketWatch
Jan-12-17 02:34PM  KemPharm CEO On Recent Results, Catalysts And Prospects: 'ADHD Is By Far The Larger Market Opportunity'
02:00PM  Lawsuit accuses Shire of monopolizing market for ADHD drug at
12:20PM  Drug makers, auto stocks yank European stocks lower for first time in 3 days at MarketWatch
Jan-11-17 08:23PM  PRESS DIGEST- Financial Times - Jan 12 Reuters
04:32PM  [$$] Shire to Pay $350 Million to Settle Dermagraft Kickback Allegations at The Wall Street Journal
02:45PM  Pharmaceutical company agrees to landmark settlement in Tampa federal court at
01:40PM  Trump slams drug industry at press conference, sending biotech stocks tumbling at
12:21PM  FTSE 100 logs 10th day of all-time highs at MarketWatch
Jan-10-17 01:17PM  Shire CEO: Our innovation score is very high
Jan-09-17 05:35PM  Martin Whitman Invests in Homebuilder in 4th Quarter
01:55PM  Merrimack Pharma to Sell Cancer Drugs for $1B at Investopedia
Jan-06-17 04:22PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
10:46AM  For Shire PLC (ADR) (SHPG) Securing Hemophilia Market With Long Acting Version Is Crucial at Insider Monkey
Jan-05-17 02:40PM  Here's what to expect from Mass. biotechs at this weekend's J.P. Morgan conference at
12:52PM  Cooperman's best ideas: 14 stock picks
12:03PM  Billionaire James Dinan Betting On These Stocks To Recover Losses at Insider Monkey
Jan-04-17 05:14PM  SHIRE PLC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
09:30AM  Shire to Present at the 35th Annual J.P. Morgan Healthcare Conference PR Newswire
Jan-03-17 05:31PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
Dec-30-16 06:17AM  Pharma Stock Roundup: Cempra Plunges to 52-Week Low, Shire Drug Label Expanded
Dec-28-16 10:18AM  Shire Gets FDA Approval for Label Expansion of Adynovate
08:15AM  Blog Coverage Shire Receives FDA Approval for ADYNOVATE for Use in Children Under 12 Years Accesswire
Dec-27-16 07:00AM  Shire Announces FDA Approval of Adynovate® for use in Children and Surgical Settings PR Newswire
06:00AM  Most Important Mergers and Acquisitions of 2016 at Investopedia
Dec-23-16 05:12PM  Third Avenue Value Fund Buys 2 Stocks and Adds to 2 Positions in Q4
Dec-22-16 11:20AM  Shire Could Have A Game Changer In The Making
11:10AM  AmerisourceBergen urges stockholders to reject unsolicited 'mini-tender' offer at
Dec-19-16 03:59PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
07:35AM  The Most Expensive Drugs of 2016 at Motley Fool
Dec-16-16 01:04PM  5 Biggest Acquisitions of 2016 at Motley Fool
Dec-15-16 01:00PM  American Blood Gives a Boost to Asias Most Valuable Drugmaker at Bloomberg
11:48AM  Shire PLC (ADR) (SHPG) Looks To Xenetic Biosciences Inc (XBIO) To Cement Hemophilia Market Share at Insider Monkey
09:47AM  A Primer On NASH
01:39AM  Is Shinhan Financial Group Co., Ltd. (ADR) (SHG) Going To Burn Investors? at Insider Monkey
Dec-09-16 04:12PM  Allergan Unhappy with Patent Office Decision to Allow Mylan Challenge to Restasis Patents
03:38PM  Best Midcap Stocks To Buy According To Billionaire Loeb at Insider Monkey
Dec-05-16 08:15AM  Blog Coverage Shire Announced Successful Results of its Phase III Investigational Study of VONVENDI(TM) Accesswire
Dec-04-16 06:05PM  5 Healthcare Stocks Billionaires Love The Most at Insider Monkey
Dec-02-16 05:21PM  Shire Reports on Four Decades of Real-World Safety Experience With FEIBA® PR Newswire
04:32PM  Shire Loses Ground To Allergan In Thanksgiving Week Dry-Eye Scripts
04:16PM  SHIRE PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
11:02AM  Topline Results of Phase 3 Investigational Study of VONVENDI Meets Primary Endpoint Effectively Controlling Bleeding and Blood Loss During Surgical Procedures PR Newswire
08:36AM  Coverage initiated on Shire plc by Societe Generale
Dec-01-16 04:29PM  John Paulson's Largest 3rd Quarter Trades
12:42PM  Is Smart Money Turning More Positive on Bed Bath & Beyond Inc. (BBBY)? at Insider Monkey
09:30AM  What Does Smart Money Think about Avery Dennison Corp (AVY)? at Insider Monkey
Nov-30-16 09:58AM  Momenta/Shire's Humira Biosimilar Meets Study Objective
Nov-29-16 08:23AM  Momenta stock jumps nearly 10% on positive late-stage results for Humira biosimilar at MarketWatch
Nov-28-16 04:34PM  Amicus Tumbles on Lengthy Delay to U.S. Fabry Drug FDA Filing Plan
01:11PM  5 Healthcare Stocks Hedge Funds Are Dumping Like Crazy at Insider Monkey
Nov-25-16 05:18AM  Actelion Soars as Johnson & Johnson 'Makes Takeover Proposal'
Nov-24-16 03:31PM  Do Hedge Funds Love PulteGroup, Inc. (PHM)? at Insider Monkey
Nov-23-16 04:00PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
01:42PM  Top Investors Are Abandoning Shire PLC (SHPG) in Droves at Insider Monkey
Nov-22-16 10:29AM  Shire to lease Genzyme headquarters, plans to hire another 400 at
07:00AM  Shire to Establish Rare Disease Innovation Hub in Cambridge, Mass. PR Newswire
Nov-21-16 02:20PM  Hayman Capital Closes Huge McDonalds (MCD) Put Position, Turns Its Bearish Gaze on This Health Stock at Insider Monkey
Nov-17-16 11:10PM  Shire Launches Cuvitru in U.S. for Primary Immunodeficiency
Nov-16-16 07:00AM  Shire Launches CUVITRU in the U.S. for Primary Immunodeficiency PR Newswire
Nov-14-16 09:57AM  Trump Supporters Icahn, Paulson Score Huge Returns After Election Win at Insider Monkey
Nov-12-16 07:00AM  Tolerability Data for Shire's CUVITRU Accepted for Oral Presentation at the American College Of Allergy, Asthma & Immunology Annual Meeting PR Newswire
Nov-10-16 05:29PM  5 Stocks to Watch on Icahn & Paulson's Gain from Trump Win
01:04PM  SHIRE PLC Financials
07:00AM  Shire's Investor Day Showcases Strength of Rare Disease Pipeline and Commercial Portfolio PR Newswire
02:37AM  Pharma stocks propel European stocks higher after Trump win shakes markets at MarketWatch
Nov-09-16 12:24PM  FTSE 100 ends roller-coaster day higher as Trump win boosts pharma, gold shares at MarketWatch +11.50%
09:52AM  Why Merrimack Pharmaceuticals, Inc. Shares Sank 18% Lower in October at Motley Fool
Nov-07-16 12:59PM  ETFs with exposure to Shire Plc : November 7, 2016
Nov-05-16 12:12AM  [$$] Big Hit on Drug Stocks Caps $26 Billion Decline for John Paulson at The Wall Street Journal
Nov-04-16 07:21PM  Samuel Isaly Makes 9 New Buys in 3rd Quarter
Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; ELVANSE/TYVENSE; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, it offers FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. Further, the company provides REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. Additionally, it offers FOSRENOL for the treatment of hyperphosphatemia in end stage renal disease; XAGRID for the reduction of elevated platelet counts; and CINRYZE, a C1 esterase inhibitor therapy for routine prophylaxis against hereditary angioedema. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. Shire plc markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. The company sells its products in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc has research collaboration with Santaris Pharma A/S. The company was founded in 1986 and is headquartered in Dublin, Ireland.